Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis

Ferring Pharma Announces EU Launch Of CORTIMENT®MMX® (budesonide) For Ulcerative Colitis
Ferring Pharmaceuticals recently announced the European launch of CORTIMENT® MMX® (budesonide) to address active mild and moderate ulcerative colitis (UC) — the first and only approved oral drug for the disease. The company has also released more data concerning the CONTRIBUTE trial, which revealed that CORTIMENT®MMX® 9 mg was significantly more effective in comparison to placebo in inducing combined clinical and endoscopic remission in

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *